Related Experiment Video
Updated: Jun 15, 2026
11:49
Autologous Endothelial Progenitor Cell-Seeding Technology and Biocompatibility Testing For Cardiovascular Devices in Large Animal Model
Published on: September 9, 2011
Beyond cell capture: antibody conjugation improves hemocompatibility for vascular tissue engineering applications
Mark Seow Khoon Chong1, Swee-Hin Teoh, Erin Yiling Teo
1Experimental Fetal Medicine Group, Department of Obstetrics and Gynaecology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore. mark@nus.edu.sg
Tissue Engineering. Part A
|March 11, 2010
Summary
CD34 antibody conjugation on polycaprolactone films significantly improved hemocompatibility by reducing platelet activation and improving blood compatibility. This advancement is crucial for cardiovascular implant applications.
Area of Science:
- Biomaterials Science
- Cardiovascular Engineering
- Surface Chemistry
Background:
- Cardiovascular implants require surfaces that promote endothelialization and exhibit hemocompatibility.
- Limited understanding exists regarding the acute blood response to antibody-conjugated surfaces used for endothelial progenitor cell capture.
Purpose of the Study:
- To investigate the hemocompatibility of polyacrylic acid (PAAc)-grafted and CD34 antibody-conjugated polycaprolactone (PCL) films.
- To determine if CD34 antibody conjugation mitigates procoagulatory events and enhances blood compatibility for implant applications.
Main Methods:
- Modification of biaxially stretched PCL films with PAAc and subsequent CD34 antibody conjugation.
- Hemocompatibility testing including contact activation, platelet adhesion/activation assays, and thromboelastography.
- Evaluation of blood compatibility index and clotting parameters.
Main Results:
- CD34 antibody-conjugated PCL films (PCL-PAAC-CD34) showed a 4- to 9-fold reduction in platelet activation compared to PCL.
- PCL-PAAc films exhibited increased contact activation and lower blood compatibility.
- PCL-PAAC-CD34 films demonstrated delayed clot formation, reduced platelet adhesion/activation, and the highest blood compatibility index (69.3%).
Conclusions:
- CD34 antibody conjugation significantly enhances the hemocompatibility of PAAc-modified PCL surfaces.
- These findings suggest potential for improved cardiovascular implant performance through tailored surface functionalization.
